GH Research PLC (NASDAQ: GHRS)

GH Research PLC (GHRS), a clinical-stage biopharmaceutical company, is dedicated to developing novel and proprietary mebufotenin therapies for the treatment of psychiatric and neurological disorders. The company's primary product candidate, GH001, is an inhalable mebufotenin product candidate being developed for the treatment of treatment-resistant depression (TRD). Incorporated in Ireland, GH Research PLC's principal place of business is in Dublin, and it trades on the NASDAQ stock exchange under the symbol GHRS.

The company's business activities are centered on developing mebufotenin therapies, a serotonergic psychedelic that acts primarily through an agonist action on serotonin receptors and causes an altered state of consciousness. GH Research PLC's operations span across various countries, with a primary focus on TRD. The company's product pipeline includes GH001, GH002, and GH003, all of which are mebufotenin product candidates being developed for the treatment of psychiatric and neurological disorders. GH Research PLC has completed two Phase 1 clinical trials in healthy volunteers for GH001 and is currently recruiting for a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial in TRD.

GH Research PLC generates revenue through the development and commercialization of its mebufotenin product candidates. Its primary product, GH001, has demonstrated safety and efficacy in several clinical trials. The company's competitive advantage lies in its mebufotenin product candidates' potential to induce ultra-rapid and durable remissions in patients with TRD, with a high propensity to induce intense psychoactive effects and a lack of clinically relevant tolerance development. This sets GH Research PLC apart from existing treatments for depression, which often have slow onset of response, poor therapy adherence rates, and various side effects.

The company's customer base includes patients with TRD, bipolar disorder II (BDII), and postpartum depression (PPD). GH Research PLC's products are designed to provide a convenient and efficient treatment option for these patients, who often have limited treatment options and may experience significant side effects with existing treatments.

GH Research PLC's product portfolio includes the following brands and/or trade names: GH001, GH002, and GH003. These product candidates are being developed for the treatment of psychiatric and neurological disorders, with a primary focus on TRD. The company's lead product, GH001, has demonstrated promising results in clinical trials, demonstrating its potential as a transformative treatment option for patients with TRD.